Exhibit 99.1
Response Biomedical Announces Strategic Realignment of Resources
VANCOUVER, British Columbia--(BUSINESS WIRE)--September 13, 2010--Response Biomedical
Corporation (TSX: RBM, OTCBB: RPBIF) today announced that the Company is taking steps to strategically
refocus its resources and has implemented a company-wide cost-cutting initiative. As a result, the Company is
expecting expense reductions of approximately $2 million in 2011 based on current sales levels. This $2 million
savings will be recognized with an approximate 25% reduction in our workforce, with the potential for other cost-
savings, moving forward.
The Company is prioritizing its resources and focusing its efforts on the growth of the cardiovascular business
through its partnership with Roche Diagnostics and through international distributorships in China, Japan, Europe
and the Middle East. The restructuring and refocus of the organization was driven in part by 3M’s decision not to
proceed with development of the next generation flu product. While Response Biomedical will continue to
support 3M’s efforts in the U.S., the Company does not expect a significant negative impact on our near term
revenue, caused by their decision regarding not proceeding with the second generation flu product.
“We are determined to take advantage of the opportunity to accelerate sales growth and shorten the timeline to
profitability by leveraging our emerging leadership in cardiovascular POCT,” said S. Wayne Kay, Chief
Executive Officer. “We offer customers a complete cardiovascular menu and with the launch of the RAMP® 200
system overseas, we will focus our organization on commercial operations moving forward. We see immediate
potential for further growth in China and we will be adding resources there. As well, we have added a sales
manager for Europe, the Middle East and Africa, and we anticipate strong growth from these markets. We will
continue to support 3M in their commercial operations efforts in the infectious diseases product line i